{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:34:41Z","timestamp":1790634881233,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"HOYA Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10384-018-00644-5","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T07:38:59Z","timestamp":1546414739000},"page":"181-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Night-vision aid using see-through display for patients with retinitis pigmentosa"],"prefix":"10.1007","volume":"63","author":[{"given":"Yasuhiro","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Nakatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Funatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohta","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Hisatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Enaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"key":"644_CR1","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849\u201360.","journal-title":"Lancet."},{"key":"644_CR2","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","volume":"372","author":"JW Bainbridge","year":"2015","unstructured":"Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, et al. Long-term effect of gene therapy on Leber\u2019s congenital amaurosis. N Engl J Med. 2015;372:1887\u201397.","journal-title":"N Engl J Med."},{"key":"644_CR3","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","volume":"372","author":"SG Jacobson","year":"2015","unstructured":"Jacobson SG, Cideciyan AV, Aguirre GD, Sumaroka A, Schwartz SB, Heon E, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372:1920\u20136.","journal-title":"N Engl J Med."},{"key":"644_CR4","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1056\/NEJMc1509501","volume":"374","author":"TL Edwards","year":"2016","unstructured":"Edwards TL, Jolly JK, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, et al. Visual Acuity after Retinal Gene Therapy for Choroideremia. N Engl J Med. 2016;374:1996\u20138.","journal-title":"N Engl J Med."},{"key":"644_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","volume":"385","author":"SD Schwartz","year":"2015","unstructured":"Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt\u2019s macular dystrophy: follow-up of two open-label phase 1\/2 studies. Lancet. 2015;385:509\u201316.","journal-title":"Lancet."},{"key":"644_CR6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","volume":"376","author":"M Mandai","year":"2017","unstructured":"Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376:1038\u201346.","journal-title":"N Engl J Med."},{"key":"644_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/archopht.1973.01000050114008","volume":"90","author":"EL Berson","year":"1973","unstructured":"Berson EL, Mehaffey L 3rd, Rabin AR. A night vision device as an aid for patients with retinitis pigmentosa. Arch Ophthalmol. 1973;90:112\u20136.","journal-title":"Arch Ophthalmol."},{"key":"644_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/archopht.1974.03900060509018","volume":"91","author":"EL Berson","year":"1974","unstructured":"Berson EL, Mehaffey L 3rd, Rabin AR. A night vision pocketscope for patients with retinitis pigmentosa: design considerations. Arch Ophthalmol. 1974;91:495\u2013500.","journal-title":"Arch Ophthalmol."},{"key":"644_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S0161-6420(83)34418-3","volume":"90","author":"DL Morrissette","year":"1983","unstructured":"Morrissette DL, Marmor MF, Goodrich GL. An evaluation of night vision mobility aids. Ophthalmology. 1983;90:1226\u201330.","journal-title":"Ophthalmology."},{"key":"644_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s004170050207","volume":"237","author":"C Friedburg","year":"1999","unstructured":"Friedburg C, Serey L, Sharpe LT, Trauzettel-Klosinski S, Zrenner E. Evaluation of the night vision spectacles on patients with impaired night vision. Graefes Arch Clin Exp Ophthalmol. 1999;237:125\u201336.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"644_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00006324-200201000-00011","volume":"79","author":"UH Spandau","year":"2002","unstructured":"Spandau UH, Wechsler S, Blankenagel A. Testing night vision goggles in a dark outside environment. Optom Vis Sci. 2002;79:39\u201345.","journal-title":"Optom Vis Sci."},{"key":"644_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1475-1313.2004.00228.x","volume":"24","author":"AR Bowers","year":"2004","unstructured":"Bowers AR, Luo G, Rensing NM, Peli E. Evaluation of a prototype minified augmented-view device for patients with impaired night vision. Ophthalmic Physiol Opt. 2004;24:296\u2013312.","journal-title":"Ophthalmic Physiol Opt."},{"key":"644_CR13","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1167\/iovs.03-1061","volume":"45","author":"DT Hartong","year":"2004","unstructured":"Hartong DT, Jorritsma FF, Neve JJ, Melis-Dankers BJ, Kooijman AC. Improved mobility and independence of night-blind people using night-vision goggles. Invest Ophthalmol Vis Sci. 2004;45:1725\u201331.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"644_CR14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1475-1313.2006.00392.x","volume":"26","author":"DT Hartong","year":"2006","unstructured":"Hartong DT, Kooijman AC. Night-vision goggles for night-blind subjects: subjective evaluation after 2 years of use. Ophthalmic Physiol Opt. 2006;26:490\u20136.","journal-title":"Ophthalmic Physiol Opt."},{"key":"644_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10384-014-0354-0","volume":"59","author":"Y Ikeda","year":"2015","unstructured":"Ikeda Y, Suzuki E, Kuramata T, Kozaki T, Koyama T, Kato Y, et al. Development and evaluation of a visual aid using see-through display for patients with retinitis pigmentosa. Jpn J Ophthalmol. 2015;59:43\u20137.","journal-title":"Jpn J Ophthalmol."},{"key":"644_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/eye.2009.176","volume":"24","author":"T Sugawara","year":"2010","unstructured":"Sugawara T, Hagiwara A, Hiramatsu A, Ogata K, Mitamura Y, Yamamoto S. Relationship between peripheral visual field loss and vision-related quality of life in patients with retinitis pigmentosa. Eye (Lond). 2010;24:535\u20139.","journal-title":"Eye (Lond)."}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-018-00644-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-018-00644-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-018-00644-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:26:15Z","timestamp":1577924775000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-018-00644-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1007\/s10384-018-00644-5","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,2]]},"assertion":[{"value":"2 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Ikeda, Grant (Alcon, Bayer, HOYA, Santen), Lecture fees (Alcon, Bayer, HOYA, Nidek, Santen); S. Nakatake, None; J. Funatsu, None; K. Fujiwara, None; T. Tachibana, None; Y. Murakami, Grant (Rohto, Santen); T. Hisatomi, Grant (Alcon, Bayer, Santen); S. Yoshida, Grant (Bonac), Lecture fees (Alcon, Bayer); H. Enaida, Grant (Alcon), Donation (HOYA, Santen), Equipment (Nidek), Lecture fees (Alcon, Santen); T. Ishibashi, Lecture fees (Alcon, Bausch + Lomb, Bayer, Chuo Sangio, HOYA, Kowa, Novartis, Santen); K. Sonoda, Grant (Alcon, HOYA, Santen), Lecture fees (AbbVie, Alcon, Santen, Wakamoto).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}